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Peter Gaines is to be thanked for drawing our attention
to his concerns regarding the CE marking for iliac
stents (EJVES 29, 105 (2005)).
I think his comments are not confined solely to iliac
stents but indeed also apply to a number of other
cardiovascular implants. As I have been personally
involved with BSI (British), CEN (European), and ISO
(International) Committees writing standards for
cardiovascular implants for many years I do under-
stand and share many of his concerns regarding the
standard of uniformity of Notified Bodies throughout
the EU who can grant a CE mark to manufacturers for
their products and the sometimes lack of adequate
mandatory pre- and post-market surveillance of
implants especially when modifications are made to
existing implants. Whereas for manufacturers to
obtain a CE mark for their cardiovascular implants,
if to be used within the European Union is, by
European law, mandatory, sadly the use of a CEN
Standard to obtain the CE mark, is not. Any standard
or literature to support their application can be used
and is often submitted. I can assure Gaines that I and
all of my European clinical colleagues have for years
fought and to a large extent succeeded in writing into
the present CEN Standards clauses to ensure that
appropriate pre- and post-marketing studies are
carried out. Also a great strength of the CEN Standard
is the section of pre-clinical evaluation bench and
analytical tests which are required to be carried out.
The constant debate at standards committee meetings
is the clinicians would like to see a time frame of pre-
and post-market surveillance which would result in
the project being financially non viable to manufac-
turers. However, I have frequently reminded manu-
factures that they are potential patients too! The1078–5884/000451+ 01 $35.00/0 q 2005 Elsevier Ltd. All rights reserpresent ISO Standard for Endovascular prostheses
has a robust section for pre- and post-market
surveillance but the standard is not mandatory for
manufactures to use. However, as many of these
services are manufactured in the USA it would not be
surprising if the FDA use the present ISO standard as a
vital yardstick. Certainly, the ISO standard on vascular
stents at present in preparation will be strong in pre-
and post-market surveillance requirements.
CEN and ISO work very closely together and a
number of their standards have been harmonised over
the years, so hopefully one day, it would be mandated
that all companies worldwide must comply with the
harmonised CEN/ISO standards. In the meantime, it
behoves all implanters to ask the manufacturer what
pre- and post-market studies have been performed on
their implants and also specific to the UK inform the
Medicines and Healthcare Products Regulatory
Agency (MHRA) in London of any adverse invents
involving any cardiovascular implant. I can also
assure Gaines that as a result of pressure mainly
from the UK regarding our concern over the lack of
clinical data supporting the CE marking of some
devices that a Commission Task Force has been
formed which has already produced a number of
guidance documents for Notified Bodies to use and
this issue is also being monitored by the Notified
Bodies Oversight Group which is at present chaired by
the UK.
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